Press Releases InterCure Ltd.

Equities

INCR

IL0011063760

Healthcare Facilities & Services

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 02:59:06 2026-04-13 am EDT			5-day change	1st Jan Change
238.10 ^ILa	0.00%		+0.55%	-26.42%

Mar. 03	InterCure Receives Noncompliance Notice From Nasdaq	MT
Mar. 03	InterCure receives Nasdaq notification regarding minimum bid requirement	RE

Press Releases

Mar. 03	InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement	AQ
Feb. 19	InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million	AQ
Nov. 03	InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation	AQ
25-10-08	InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow	AQ
25-09-19	InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands	AQ
25-05-01	InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025	PR
25-02-12	InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak	PR
25-02-03	InterCure : Immediate Report	PU
25-02-02	InterCure : A meeting to be held on February 3, 2025-Amendment regarding the private placement	PU
25-01-27	InterCure : Immediate Report	PU
24-12-20	InterCure : NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 27, 2025 Form 6 K	PU
24-12-20	InterCure : has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility Form 6 K	PU
24-12-20	InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility	PR
24-11-25	InterCure : Immediate Report of Meeting	PU
24-11-25	InterCure : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 30, 2024 Form 6 K	PU
24-11-04	InterCure : Immediate Report	PU
24-10-28	InterCure : Immediate Report	PU
24-08-29	InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million	AQ
24-08-28	InterCure Announces Expansion of its Strategic partnership with Cookies to Germany	BU
24-05-22	InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference	BU
24-05-21	InterCure : Immediate Report	PU
24-05-01	InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million	BU
24-05-01	InterCure : FORM 20-F For the fiscal year ended December 31, 2023	PU
24-05-01	InterCure : Announces FY2023 Result	PU
24-04-01	InterCure : Preliminary results for the full year of 2023	PU